Business Context and Reporting Period
This Form 8-K reports the results of the reconvened Annual Meeting of Stockholders for Artele Biosciences, Inc. held on January 30, 2026. The meeting was previously adjourned on December 31, 2025, due to a lack of quorum. As of the record date (December 10, 2025), the company had 2,018,746 shares of Common Stock outstanding. The reconvened meeting achieved a quorum with 1,017,816 shares represented (approximately 50.4% of outstanding shares).
Key Financial Metrics
This filing is a Current Report regarding corporate governance and voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material event reported is the successful reconvening of the Annual Meeting after a prior failure to achieve a quorum. The following matters were voted upon and resolved:
- Election of Directors: Two Class II directors, Douglas Blayney, M.D., and Connie Matsui, were re-elected to serve until the 2028 annual meeting.
- Executive Compensation: The advisory "say-on-pay" proposal was approved.
- Auditor Ratification: The appointment of Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors. The only notable contingency mentioned is the prior failure to achieve a quorum on December 31, 2025, which necessitated the reconvening of the meeting.
Investor Verification Checklist
- Verify the re-election of Douglas Blayney, M.D., and Connie Matsui as Class II directors.
- Confirm the approval of the "say-on-pay" advisory vote (158,971 For vs. 126,089 Against).
- Note the ratification of Malone Bailey LLP as the independent auditor for the 2026 fiscal year.
- Review the voting breakdown for the director elections, noting significant broker non-votes (633,102) for both nominees.